Daxor Corporation Announces Two New Studies From the Mayo Clinic and Lankenau Medical Center Presented at Heart Failure Socie...
September 29 2016 - 8:30AM
Marketwired
Daxor Corporation Announces Two New Studies From the Mayo Clinic
and Lankenau Medical Center Presented at Heart Failure Society of
America 2016 Highlight Unique Ability of BVA to Identify High Risk
at Discharge in Hospitalized Heart Failure Patients
NEW YORK, NY-(Marketwired - Sep 29, 2016) - Daxor Corporation
(NYSE MKT: DXR), an investment company with medical instrumentation
and biotechnology operations, announces two new studies presented
at the Heart Failure Society of America meeting this month
highlighting risks for hospitalized heart failure patients
detectable by direct blood volume measurement (Daxor BVA-100).
Michael Feldschuh, President and CEO of Daxor, stated, "These
new studies reinforce the outcomes presented earlier this year in
the same arena showing the importance of direct blood volume
analysis for improving heart failure results. It is only with the
unique technology of Daxor's BVA-100 and not with standard current
tests that clinicians are able to precisely measure the volume
derangements underlying heart failure, and these results highlight
the importance of treating in the light of that information. Anemia
and hypervolemia are known killers in this disease setting, yet in
the absence of blood volume analysis no reliable test for
quantifying either is available."
Wayne L. Miller, MD, PhD (Mayo Clinic, Rochester, MN) reported
outcomes by red blood cell volume status in 50 hospitalized heart
failure patients with decompensated chronic heart failure
observationally assessed by blood volume analysis at discharge.
Notably, red blood cell volume at discharge was markedly
heterogeneous in this cohort, ranging from a deficit of 32% to an
excess of +101% vs. calculated patient-specific ideal.
True anemia measured at discharge was associated with a high
early risk of heart failure mortality or re-hospitalization in the
Mayo Clinic study: 50% in the first 6 months. Importantly, true
anemia at discharge associated with a high risk of poor outcomes
was identifiable only by blood volume analysis. Specifically, a
blood volume analysis measured red blood cell volume deficit at
discharge was predictive of heart failure mortality or
re-hospitalization. By contrast, conventional peripheral venous
serum hemoglobin at discharge was not predictive of heart failure
or re-hospitalization. Serum hemoglobin is well understood to be
clinically unreliable in heart failure, as it is confounded by the
plasma volume derangement characteristically observed in these
patients, but it is widely referred to where blood volume analysis
is unavailable.
Suggested Dr. Miller: "Is true anemia an under-treated target
that if addressed could result in better short- and long-term
survival and reduced frequency of heart failure-related
re-hospitalizations?"
A second dataset was presented by Christopher J. Droogan, DO,
and colleagues (Lankenau Medical Center, Wynnewood, PA) reporting
on the first study of hospitalized heart failure patients to
receive a blood volume analysis at their institution. In the
Lankenau analysis, true anemia at discharge was associated with a
62% 30-day readmissions rate. Persistent severe hypervolemia at
discharge was associated with a 50% 30-day readmissions rate. Of
those who experienced a 30-day readmission, 47% had had true anemia
at discharge and an additional 41% persistent hypervolemia, thus
88% of those patients who experienced a 30-day readmission were
identifiable as having had one of these two risk factors at
discharge. By contrast, the 18 patients - 38% of the study - who
had had normal red blood cell volume status and were normovolemic
or in less severe volume excess at the time of their discharge from
hospital achieved a 30-day readmission rate of just 11%. Both
hypervolemia and anemia are precisely quantifiable only with blood
volume analysis in heart failure.
Dr. Droogan stated, "These results underline the need to
identify and address anemia in the setting of hospitalized heart
failure. Accurate quantification of red blood cell volume status
will improve the risk-benefit of treatment and allow more proactive
management of anemia in heart failure patients."
Said Daxor's Chief Scientific Officer, Dr. Joseph Feldschuh,
"The two new datasets presented at the Heart Failure Society of
America this year confirm that true anemia matters in heart
failure, yet it has been difficult to diagnose or treat in this
population. Only blood volume analysis measures red blood cell
volume status directly, accurately, and regardless of plasma
derangement so that clinicians can flag patients at risk for poor
outcomes early and individualize the treatment strategy with
confidence."
Michael Feldschuh, President and CEO of Daxor, added, "Realizing
the potential of individualized care guided by blood volume
analysis to meaningfully improve clinical and resource utilization
outcomes in heart failure is even more urgent in the light of these
results. I am excited about the ability of this unique technology
to potentiate meaningful advances in care as we move beyond
one-size-fits-all approaches to diverse patient needs in this
heterogeneous disease area."
Blood volume analysis is the only metric to deliver consistent
accuracy in quantifying red blood cell volume status, regardless of
plasma expansion or depletion or of body size and type, as well as
enabling clinicians to measure total blood volume directly and with
98% accuracy. Volume overload is a hallmark of heart failure, and
the accurate measurement and management of congestion is a core
concern for heart failure physicians. Clinical signs and symptoms
alone are well understood to be inadequately sensitive and specific
in the evaluation of volume status; indirect metrics such as
hemodynamic pressures, while informative in other respects,
demonstrate poor correlation with measured total blood volume; and
serum red blood cell measures are confounded by plasma derangement
and thus have limited clinical utility in heart failure. Blood
volume analysis is uniquely direct, swift, and accurate in
measuring both total blood volume and red blood cell volume.
Daxor Corporation manufactures and markets the BVA-100 Blood
Volume Analyzer, which is used in conjunction with Volumex, Daxor's
single-use diagnostic kit. For more information regarding BVA and
the Daxor BVA-100, visit Daxor's website at www.Daxor.com.
Contact Information
Daxor contact information:
Michael Feldschuh
President and CEO
212-330-8506
mfeldschuh@daxor.com
Lisa Quartley
Senior Vice President
Marketing and Commercial Development
212-330-8518
lquartley@daxor.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024